- Home
- TCBI vs GRFS Comparison
TCBI vs GRFS Comparison
Compare TCBI & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCBI | GRFS |
|---|---|---|
| Founded | 1996 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.9B |
| IPO Year | 2000 | 2008 |
Fundamental Metrics
Financial Performance| Metric | TCBI | GRFS |
|---|---|---|
| Price | $93.13 | $7.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 2 |
| Target Price | ★ $106.15 | $10.87 |
| AVG Volume (30 Days) | ★ 479.9K | 445.0K |
| Earning Date | 10-21-2026 | 07-28-2022 |
| Dividend Yield | 0.86% | ★ 1.14% |
| EPS Growth | ★ 430.47 | N/A |
| EPS | ★ 3.39 | N/A |
| Revenue | ★ $149,000.00 | N/A |
| Revenue This Year | $6.70 | $1.73 |
| Revenue Next Year | $6.44 | $6.26 |
| P/E Ratio | $27.50 | ★ $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $75.41 | $6.96 |
| 52 Week High | $108.92 | $9.90 |
Technical Indicators
Market Signals| Indicator | TCBI | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 36.69 | 51.65 |
| Support Level | $89.71 | $7.44 |
| Resistance Level | $102.57 | $7.73 |
| Average True Range (ATR) | 1.62 | 0.12 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 35.57 | 91.57 |
Price Performance
Historical ComparisonAbout TCBI Texas Capital Bancshares Inc.
Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customised solutions to businesses, entrepreneurs and individual customers. It is a secured lender with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. Texas Capital has established commercial banking, consumer banking, investment banking and wealth management capabilities.
About GRFS Grifols S.A.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.